Zulvac 1+8 Bovis

RSS

Authorised

This medicine is authorised for use in the European Union

inactivated bluetongue virus, serotypes 1 and 8
MedicineVeterinaryAuthorised

Estonian is available via eTranslation, the European Commission's machine translation service.

Translate to Estonian | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website

български (BG) (93.36 KB - PDF)

Vaata

español (ES) (81.97 KB - PDF)

Vaata

čeština (CS) (93.99 KB - PDF)

Vaata

dansk (DA) (83.34 KB - PDF)

Vaata

Deutsch (DE) (82.76 KB - PDF)

Vaata

eesti (ET) (82.18 KB - PDF)

Vaata

ελληνικά (EL) (93.76 KB - PDF)

Vaata

français (FR) (82.44 KB - PDF)

Vaata

Gaeilge (GA) (83.57 KB - PDF)

Vaata

hrvatski (HR) (92.27 KB - PDF)

Vaata

italiano (IT) (82.29 KB - PDF)

Vaata

latviešu (LV) (94.29 KB - PDF)

Vaata

lietuvių (LT) (94.03 KB - PDF)

Vaata

magyar (HU) (94.15 KB - PDF)

Vaata

Malti (MT) (95.95 KB - PDF)

Vaata

Nederlands (NL) (82.05 KB - PDF)

Vaata

polski (PL) (95.62 KB - PDF)

Vaata

português (PT) (83.01 KB - PDF)

Vaata

română (RO) (94.17 KB - PDF)

Vaata

slovenčina (SK) (94.08 KB - PDF)

Vaata

slovenščina (SL) (82.27 KB - PDF)

Vaata

suomi (FI) (81.54 KB - PDF)

Vaata

svenska (SV) (82.05 KB - PDF)

Vaata

Íslenska (IS) (83.29 KB - PDF)

Vaata

norsk (NO) (82 KB - PDF)

Vaata

Product information

български (BG) (91.78 KB - PDF)

Vaata

español (ES) (81.51 KB - PDF)

Vaata

čeština (CS) (92.48 KB - PDF)

Vaata

dansk (DA) (82.05 KB - PDF)

Vaata

Deutsch (DE) (81.72 KB - PDF)

Vaata

eesti (ET) (81.22 KB - PDF)

Vaata

ελληνικά (EL) (91.79 KB - PDF)

Vaata

français (FR) (81.63 KB - PDF)

Vaata

Gaeilge (GA) (81.36 KB - PDF)

Vaata

hrvatski (HR) (91.56 KB - PDF)

Vaata

italiano (IT) (81.76 KB - PDF)

Vaata

latviešu (LV) (92.14 KB - PDF)

Vaata

lietuvių (LT) (92.19 KB - PDF)

Vaata

magyar (HU) (92.76 KB - PDF)

Vaata

Malti (MT) (93.86 KB - PDF)

Vaata

Nederlands (NL) (81.15 KB - PDF)

Vaata

polski (PL) (93.22 KB - PDF)

Vaata

português (PT) (82.53 KB - PDF)

Vaata

română (RO) (91.73 KB - PDF)

Vaata

slovenčina (SK) (81.75 KB - PDF)

Vaata

slovenščina (SL) (81.76 KB - PDF)

Vaata

suomi (FI) (81.11 KB - PDF)

Vaata

svenska (SV) (81.47 KB - PDF)

Vaata

Íslenska (IS) (81.52 KB - PDF)

Vaata

norsk (NO) (81.52 KB - PDF)

Vaata

български (BG) (93.36 KB - PDF)

Vaata

español (ES) (81.97 KB - PDF)

Vaata

čeština (CS) (93.99 KB - PDF)

Vaata

dansk (DA) (83.34 KB - PDF)

Vaata

Deutsch (DE) (82.76 KB - PDF)

Vaata

eesti (ET) (82.18 KB - PDF)

Vaata

ελληνικά (EL) (93.76 KB - PDF)

Vaata

français (FR) (82.44 KB - PDF)

Vaata

Gaeilge (GA) (83.57 KB - PDF)

Vaata

hrvatski (HR) (92.27 KB - PDF)

Vaata

italiano (IT) (82.29 KB - PDF)

Vaata

latviešu (LV) (94.29 KB - PDF)

Vaata

lietuvių (LT) (94.03 KB - PDF)

Vaata

magyar (HU) (94.15 KB - PDF)

Vaata

Malti (MT) (95.95 KB - PDF)

Vaata

Nederlands (NL) (82.05 KB - PDF)

Vaata

polski (PL) (95.62 KB - PDF)

Vaata

português (PT) (83.01 KB - PDF)

Vaata

română (RO) (94.17 KB - PDF)

Vaata

slovenčina (SK) (94.08 KB - PDF)

Vaata

slovenščina (SL) (82.27 KB - PDF)

Vaata

suomi (FI) (81.54 KB - PDF)

Vaata

svenska (SV) (82.05 KB - PDF)

Vaata

Íslenska (IS) (83.29 KB - PDF)

Vaata

norsk (NO) (82 KB - PDF)

Vaata

Product details

Name of medicine
Zulvac 1+8 Bovis
Active substance
  • inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP
  • inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02
International non-proprietary name (INN) or common name
inactivated bluetongue virus, serotypes 1 and 8

Pharmacotherapeutic group

  • Immunologicals
  • Immunologicals for Bovidae
  • Cattle
  • Inactivated viral vaccines
  • bluetongue virus

Authorisation details

EMA product number
EMEA/V/C/002473

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Assessment history

This page was last updated on

Share this page